How Adrestia Therapeutics is pioneering synthetic rescue - an interview with Prof Steve Jackson and CEO Robert Johnson


A new approach to tackling genetic diseases could unlock treatments to some of the most intractable conditions, it is hoped.

Spinning out of the academic research of Prof Steve Jackson at the University of Cambridge in 2018, Adrestia Therapeutics is focused on synthetic rescue as a means of developing therapeutics.

The company, which employs 30 people on Babraham Research Campus, recently appointed Robert Johnson as its first full-time CEO and is focused on taking its pipeline into the clinic – and then to market, as a fully integrated pharmaceutical company.

To read the full article please click here.